Publications by authors named "Laetitia Maillot"
Article Synopsis
- - Atypical teratoid rhabdoid tumors (ATRT) are classified into MYC, TYR, and SHH subgroups, indicating different possible origins of these tumors.
- - Research shows that MYC tumors may originate outside the brain, while SHH ATRT can arise from specific brain regions like the cerebellar anterior lobe and the basal ganglia, confirmed by single-cell RNA sequencing.
- - Analysis indicates that losing the SMARCB1 gene leads to a de-differentiation in SHH ATRT, influenced by factors that suppress neuron differentiation, such as REST and the NOTCH pathway.
Pediatric Chordomas: Results of a Multicentric Study of 40 Children and Proposal for a Histopathological Prognostic Grading System and New Therapeutic Strategies.
J Neuropathol Exp Neurol
March 2018
Pediatric chordomas are rare malignant neoplasms, and few data are available for optimizing therapeutic strategies and outcome. This study aimed at evaluating how best to manage them and to identify prognostic factors. This multicentric retrospective study included 40 children diagnosed with chordomas between 1966 and 2012.
View Article and Find Full Text PDFArticle Synopsis
- * High-throughput screening of approved drugs revealed pazopanib and clofilium tosylate (CfT) as promising candidates, with pazopanib specifically targeting key tyrosine kinase receptors (RTKs) that are frequently expressed in RTs.
- * The combination of pazopanib and CfT not only enhanced tumor growth reduction in vivo but also matched the effectiveness of traditional chemotherapy, suggesting potential for future clinical trials.
Extra-cranial rhabdoid tumors (RT) are highly aggressive malignancies of infancy, characterized by undifferentiated histological features and loss of SMARCB1 expression. The diagnosis is all the more challenging that other poorly differentiated cancers lose SMARCB1 expression, such as epithelioid sarcomas (ES), renal medullary carcinomas (RMC) or undifferentiated chordomas (UC). Moreover, late cases occurring in adults are now increasingly reported, raising the question of differential diagnoses and emphasizing nosological issues.
View Article and Find Full Text PDFBackground: Renal medullary carcinoma (RMC) is a rare and highly aggressive neoplasm that most often occurs in the setting of sickle cell trait or sickle cell disease (SCD). Most patients present with metastatic disease resistant to conventional chemotherapy, and therefore there is an urgent need for molecular insight to propose new therapies.
Objective: To determine the molecular alterations and oncogenic pathways that drive RMC development.